Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ CIDEC Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA146128
Description
Suggested positive control: antigen standard for CIDEC (transient overexpression lysate).
DNA fragmentation is one of the critical steps in apoptosis, which is induced by DNA fragmentation factor (DFF). DFF is composed of two subunits, a 40 kDa caspase-activated nuclease (DFF40) and a 45 kDa inhibitor (DFF45). Recently a novel family of cell-death-inducing DFF45-like effectors (CIDEs) has been identified. Human CIDE-3 is a novel member of CIDEs. There are 2 transcripts, CIDE-3 and CIDE-3alpha, were present in HepG2 and A375 cells. Consistent with its chromosome localization at 3p25, a region associated with high frequency loss of heterozygosity in many tumours, CIDE-3 may play an important role in prevention of tumorigenesis.
Specifications
CIDEC | |
Polyclonal | |
Unconjugated | |
CIDEC | |
cell death activator CIDE-3; cell death inducing DFFA like effector c; cell death-inducing DFFA-like effector c; cell death-inducing DFFA-like effector protein C; CID; cide 3; CIDE3; CIDE-3; CIDE-3alpha; Cidec; fat specific gene 27; fat specific protein 27; fat-specific protein FSP27; Fat-specific protein FSP27 homolog; FPLD5; FSP27 | |
Rabbit | |
Antigen affinity chromatography | |
RUO | |
14311, 500292, 63924 | |
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
Liquid |
Western Blot, Immunocytochemistry | |
1 mg/mL | |
PBS with 0.02% sodium azide | |
P56198, Q5XI33, Q96AQ7 | |
CIDEC | |
Residues 10-25 of human CIDE-3 protein. | |
100 μL | |
Primary | |
Human, Mouse, Rat | |
Antibody | |
IgG |
Safety and Handling
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction